Literature DB >> 31076878

Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay-Sachs disease.

Helena Jahnová1, Helena Poupětová1, Jitka Jirečková1, Hana Vlášková1, Eva Košťálová1, Radim Mazanec2, Alena Zumrová3, Petr Mečíř4, Zuzana Mušová5, Martin Magner6.   

Abstract

BACKGROUND: Tay-Sachs disease (TSD) is an inherited neurodegenerative disorder caused by a lysosomal β-hexosaminidase A deficiency due to mutations in the HEXA gene. The late-onset form of disease (LOTS) is considered rare, and only a limited number of cases have been reported. The clinical course of LOTS differs substantially from classic infantile TSD.
METHODS: Comprehensive data from 14 Czech patients with LOTS were collated, including results of enzyme assays and genetic analyses.
RESULTS: 14 patients (9 females, 5 males) with LOTS were diagnosed between 2002 and 2018 in the Czech Republic (a calculated birth prevalence of 1 per 325,175 live births). The median age of first symptoms was 21 years (range 10-33 years), and the median diagnostic delay was 10.5 years (range 0-29 years). The main clinical symptoms at the time of manifestation were stammering or slurred speech, proximal weakness of the lower extremities due to anterior horn cell neuronopathy, signs of neo- and paleocerebellar dysfunction and/or psychiatric disorders. Cerebellar atrophy detected through brain MRI was a common finding. Residual enzyme activity was 1.8-4.1% of controls. All patients carried the typical LOTS-associated c.805G>A (p.Gly269Ser) mutation on at least one allele, while a novel point mutation, c.754C>T (p.Arg252Cys) was found in two siblings.
CONCLUSION: LOTS seems to be an underdiagnosed cause of progressive distal motor neuron disease, with variably expressed cerebellar impairment and psychiatric symptomatology in our group of adolescent and adult patients. The enzyme assay of β-hexosaminidase A in serum/plasma is a rapid and reliable tool to verify clinical suspicions.

Entities:  

Keywords:  Ataxia; Cerebellum; GM2 gangliosidosis; Late-onset Tay–Sachs disease; Proximal weakness of lower extremities; β-Hexosaminidase A

Mesh:

Year:  2019        PMID: 31076878     DOI: 10.1007/s00415-019-09364-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Late-onset Tay-Sachs disease.

Authors:  Orit Neudorfer; Edwin H Kolodny
Journal:  Isr Med Assoc J       Date:  2004-02       Impact factor: 0.892

Review 2.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

3.  Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients.

Authors:  Orit Neudorfer; Gregory M Pastores; Bai J Zeng; John Gianutsos; Charles M Zaroff; Edwin H Kolodny
Journal:  Genet Med       Date:  2005-02       Impact factor: 8.822

4.  Psychiatric features of adult GM2 gangliosidosis.

Authors:  J Streifler; M Golomb; N Gadoth
Journal:  Br J Psychiatry       Date:  1989-09       Impact factor: 9.319

5.  Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

Authors:  Stuart A Scott; Lisa Edelmann; Liu Liu; Minjie Luo; Robert J Desnick; Ruth Kornreich
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

6.  Cerebellar atrophy and muscle weakness: late-onset Tay-Sachs disease outside Jewish populations.

Authors:  Katharina Marie Steiner; Johannes Brenck; Sophia Goericke; Dagmar Timmann
Journal:  BMJ Case Rep       Date:  2016-03-31

7.  Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model.

Authors:  M M Kaback
Journal:  Eur J Pediatr       Date:  2000-12       Impact factor: 3.183

8.  The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease.

Authors:  R Navon; R L Proia
Journal:  Science       Date:  1989-03-17       Impact factor: 47.728

9.  Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.

Authors:  Barbara E Shapiro; Gregory M Pastores; John Gianutsos; Cécile Luzy; Edwin H Kolodny
Journal:  Genet Med       Date:  2009-06       Impact factor: 8.822

10.  Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study.

Authors:  Etty Osher; Aviva Fattal-Valevski; Liora Sagie; Nataly Urshanski; Nadav Sagiv; Leah Peleg; Tally Lerman-Sagie; Ari Zimran; Deborah Elstein; Ruth Navon; Avi Valevski; Naftali Stern
Journal:  Orphanet J Rare Dis       Date:  2015-04-17       Impact factor: 4.123

View more
  7 in total

1.  Autosomal recessive adult onset ataxia.

Authors:  Nataša Dragašević-Mišković; Iva Stanković; Andona Milovanović; Vladimir S Kostić
Journal:  J Neurol       Date:  2021-09-09       Impact factor: 4.849

2.  [Progressive psychomotor regression for 2.5 years in a boy aged 5 years].

Authors:  Mao-Qiang Tian; Xiao-Xi Chen; Lei Li; Chang-Hui Lang; Juan Li; Jing Chen; Xiao-Hua Yu; Xiao-Mei Shu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

3.  Pontocerebellar atrophy is the hallmark neuroradiological finding in late-onset Tay-Sachs disease.

Authors:  Jitka Májovská; Anita Hennig; Igor Nestrasil; Susanne A Schneider; Helena Jahnová; Manuela Vaněčková; Martin Magner; Petr Dušek
Journal:  Neurol Sci       Date:  2021-11-20       Impact factor: 3.830

4.  Cerebellar atrophy on top of motor neuron compromise as indicator of late-onset GM2 gangliosidosis.

Authors:  Hans Thomas Hölzer; Felix Boschann; Julia B Hennermann; Gabriele Hahn; Andreas Hermann; Maja von der Hagen; Victoria Tüngler
Journal:  J Neurol       Date:  2021-03-09       Impact factor: 4.849

5.  The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.

Authors:  Camilo Toro; Mosufa Zainab; Cynthia J Tifft
Journal:  Neurosci Lett       Date:  2021-08-25       Impact factor: 3.046

6.  Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis.

Authors:  Olivia E Rowe; D Rangaprakash; Akila Weerasekera; Neha Godbole; Elizabeth Haxton; Peter F James; Christopher D Stephen; Robert L Barry; Florian S Eichler; Eva-Maria Ratai
Journal:  Mol Genet Metab       Date:  2021-06-24       Impact factor: 4.204

7.  Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.

Authors:  Nicole Lyn; Ruth Pulikottil-Jacob; Camille Rochmann; Robert Krupnick; Chad Gwaltney; Nick Stephens; Julie Kissell; Gerald F Cox; Tanya Fischer; Alaa Hamed
Journal:  Orphanet J Rare Dis       Date:  2020-04-15       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.